{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:40:45Z","timestamp":1792503645764,"version":"4.5.0"},"reference-count":62,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CNS Neurosci Ther"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Haloperidol is a widely prescribed antipsychotic, but its long\u2010term safety profile across broad populations remains insufficiently researched. Using the large\u2010scale FDA Adverse Event Reporting System (FAERS) database, this study sought to comprehensively characterize the real\u2010world adverse event profile of haloperidol and identify potential safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adverse event reports from FAERS spanning Q1 2004 through Q1 2026, with haloperidol listed as the primary suspect drug, were analyzed. Disproportionality analyses employing four complementary algorithms (ROR, PRR, BCPNN, and MGPS) were conducted. Time\u2010to\u2010onset and Weibull distribution analyses were also performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 9916 reports associated with haloperidol were analyzed, covering 27 System Organ Classes (SOC). The primary SOCs were nervous system disorders, psychiatric disorders, and cardiac disorders. At the preferred terms (PT) level, extrapyramidal disorder, weight increased, neuroleptic malignant syndrome, tremor, and dystonia were the most frequently reported adverse events. Cardiovascular\u2010related adverse events (e.g., electrocardiogram QT prolonged, tachycardia, cardiac arrest, and torsade de pointes) were confirmed. Significantly, we identified signals for some under\u2010recognized adverse events, including suicide\u2010related behaviors (intentional self\u2010injury, suicide attempt, suicidal ideation) and embolism venous. Most adverse events occurred within the first 30\u2009days of treatment (72.03%), and the Weibull distribution indicated an early failure pattern, suggesting that the risk of adverse events gradually decreased over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This pharmacovigilance research confirmed haloperidol's established safety profile and highlighted under\u2010characterized safety signals, offering valuable insight to inform clinical surveillance, risk mitigation, and future study endeavors to optimize the safe application of haloperidol across diverse patient demographics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cns.71217","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:57:43Z","timestamp":1792501063000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Real\u2010World Safety Profile of Haloperidol: A Comprehensive Pharmacovigilance Analysis Using the Large\u2010Scale\n                    <scp>FAERS<\/scp>\n                    Database"],"prefix":"10.1002","volume":"32","author":[{"given":"Nengping","family":"Luo","sequence":"first","affiliation":[{"name":"Ganzhou Cancer Hospital  Ganzhou Jiangxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xiao","sequence":"additional","affiliation":[{"name":"Ganzhou Cancer Hospital  Ganzhou Jiangxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Science Chongqing Three Gorges Medical College  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6778-8487","authenticated-orcid":false,"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[{"name":"The Sixth People's Hospital of Chongqing The First Affiliated Hospital of Chongqing Medical and Pharmaceutical College  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"6","key":"e_1_2_14_2_1","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1176\/appi.ajp.20240305","article-title":"The Genesis of Schizophrenia: An Origin Story","volume":"181","author":"Birnbaum R.","year":"2024","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"e_1_2_14_3_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, Regional, and National Burden of 12 Mental Disorders in 204 Countries and Territories, 1990\u20102019: A Systematic Analysis for the Global Burden of Disease Study 2019","volume":"9","author":"GBD 2019 Mental Disorders Collaborators","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"e_1_2_14_4_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40273-022-01217-8","article-title":"The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost\u2010of\u2010Illness Studies","volume":"41","author":"Lin C.","year":"2023","journal-title":"PharmacoEconomics"},{"key":"e_1_2_14_5_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-pharmtox-051921-093250","article-title":"Cognitive Impairment Associated With Schizophrenia: From Pathophysiology to Treatment","volume":"63","author":"Javitt D. C.","year":"2023","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"1","key":"e_1_2_14_6_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/01612840.2022.2158683","article-title":"More Than a Half\u2010Century With Haloperidol: Glories, Disparities, and Use Today","volume":"44","author":"Mills J.","year":"2023","journal-title":"Issues in Mental Health Nursing"},{"issue":"7","key":"e_1_2_14_7_1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a Century of Antipsychotics and Still a Central Role for Dopamine D2 Receptors","volume":"27","author":"Kapur S.","year":"2003","journal-title":"Progress in Neuro\u2010Psychopharmacology & Biological Psychiatry"},{"issue":"1","key":"e_1_2_14_8_1","article-title":"Haloperidol Versus Chlorpromazine for Schizophrenia","volume":"2008","author":"Leucht C.","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_14_9_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110772","article-title":"Haloperidol in Palliative Care: Indications and Risks","volume":"132","author":"Zaporowska\u2010Stachowiak I.","year":"2020","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"8","key":"e_1_2_14_10_1","doi-asserted-by":"crossref","DOI":"10.3390\/ph17081096","article-title":"Haloperidol for Pain Management: A Narrative Review","volume":"17","author":"Roldan C. J.","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"e_1_2_14_11_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-08855-w","article-title":"Chronic Haloperidol Exposure Impairs Neurodevelopment via Notch1 Signaling in Human Stem Cell\u2010Derived Brain Organoids","volume":"15","author":"Kang H.","year":"2025","journal-title":"Scientific Reports"},{"key":"e_1_2_14_12_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2026.121240","article-title":"Adverse Events Related to Buspirone: A Real\u2010World Pharmacovigilance Study Using the FAERS Database","volume":"401","author":"Wen Z.","year":"2026","journal-title":"Journal of Affective Disorders"},{"issue":"3","key":"e_1_2_14_13_1","doi-asserted-by":"crossref","DOI":"10.1002\/cns.70836","article-title":"The Real\u2010World Safety Profile of Temazepam: A 20\u2010Year Pharmacovigilance Analysis Based on the Large\u2010Scale FAERS Database","volume":"32","author":"Wen Z.","year":"2026","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"5","key":"e_1_2_14_14_1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7150\/ijms.7967","article-title":"Commonality of Drug\u2010Associated Adverse Events Detected by 4 Commonly Used Data Mining Algorithms","volume":"11","author":"Sakaeda T.","year":"2014","journal-title":"International Journal of Medical Sciences"},{"issue":"5","key":"e_1_2_14_15_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2026.e00973","article-title":"The Real\u2010World Safety Profile of Amitriptyline: A Comprehensive Pharmacovigilance Analysis Based on the Large\u2010Scale FDA Adverse Event Reporting System Database","volume":"23","author":"Yang Y.","year":"2026","journal-title":"Neurotherapeutics"},{"key":"e_1_2_14_16_1","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/916198","article-title":"Gender Differences in Schizophrenia and First\u2010Episode Psychosis: A Comprehensive Literature Review","volume":"2012","author":"Ochoa S.","year":"2012","journal-title":"Schizophrenia Research and Treatment"},{"key":"e_1_2_14_17_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality","volume":"30","author":"McGrath J.","year":"2008","journal-title":"Epidemiologic Reviews"},{"key":"e_1_2_14_18_1","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1038\/s41380-026-03533-3","article-title":"Global Lifetime Prevalence of Schizophrenia: A Systematic Review and Meta\u2010Analysis","volume":"31","author":"Zhang S.","year":"2026","journal-title":"Molecular Psychiatry"},{"issue":"12","key":"e_1_2_14_19_1","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, Prevalence, and Global Burden of Schizophrenia\u2014Data, With Critical Appraisal, From the Global Burden of Disease (GBD) 2019","volume":"28","author":"Solmi M.","year":"2023","journal-title":"Molecular Psychiatry"},{"issue":"5","key":"e_1_2_14_20_1","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S2468-2667(19)30056-8","article-title":"International Incidence of Psychotic Disorders, 2002\u201017: A Systematic Review and Meta\u2010Analysis","volume":"4","author":"Jongsma H. E.","year":"2019","journal-title":"Lancet Public Health"},{"issue":"8","key":"e_1_2_14_21_1","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic Dose, Dopamine D2 Receptor Occupancy and Extrapyramidal Side\u2010Effects: A Systematic Review and Dose\u2010Response Meta\u2010Analysis","volume":"28","author":"Siafis S.","year":"2023","journal-title":"Molecular Psychiatry"},{"issue":"8","key":"e_1_2_14_22_1","first-page":"900","article-title":"New Trends in the Treatment of Schizophrenia","volume":"16","author":"Meltzer H. Y.","year":"2017","journal-title":"CNS & Neurological Disorders \u2010 Drug Targets"},{"issue":"4","key":"e_1_2_14_23_1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jemermed.2017.11.031","article-title":"Evidence\u2010Based Review of Pharmacotherapy for Acute Agitation. Part 2: Safety","volume":"54","author":"Zun L. S.","year":"2018","journal-title":"Journal of Emergency Medicine"},{"issue":"2","key":"e_1_2_14_24_1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12028-024-01948-w","article-title":"Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium: Randomized Controlled Trial","volume":"41","author":"Zakhary T.","year":"2024","journal-title":"Neurocritical Care"},{"issue":"10","key":"e_1_2_14_25_1","article-title":"Complex Pharmacodynamics of Aripiprazole and Haloperidol in Schizophrenia Management: A Case Report","volume":"16","author":"Farooq R.","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"e_1_2_14_26_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s13311-013-0240-3","article-title":"Treatment of Movement Disorder Emergencies","volume":"11","author":"Frucht S. J.","year":"2014","journal-title":"Neurotherapeutics"},{"key":"e_1_2_14_27_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.schres.2023.08.003","article-title":"What Clinical Analysis of Antipsychotic\u2010Induced Catatonia and Neuroleptic Malignant Syndrome Tells Us About the Links Between These Two Syndromes: A Systematic Review","volume":"262","author":"Virolle J.","year":"2023","journal-title":"Schizophrenia Research"},{"issue":"3","key":"e_1_2_14_28_1","article-title":"Haloperidol\u2010Induced Neuroleptic Malignant Syndrome: A Case Report","volume":"16","author":"Fader J. P.","year":"2024","journal-title":"Cureus"},{"key":"e_1_2_14_29_1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.toxrep.2024.03.003","article-title":"Neuroleptic Malignant Syndrome After Overdose of Haloperidol \u2010 A Case Report","volume":"12","author":"Kraaijvanger N.","year":"2024","journal-title":"Toxicology Reports"},{"issue":"3","key":"e_1_2_14_30_1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/02698811241309620","article-title":"Haloperidol Dopamine Receptor Occupancy and Antagonism Correspond to Delirium Agitation Scores and EPS Risk: A PBPK\u2010PD Modeling Analysis","volume":"39","author":"Burkat P. M.","year":"2025","journal-title":"Journal of Psychopharmacology"},{"issue":"9896","key":"e_1_2_14_31_1","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple\u2010Treatments Meta\u2010Analysis","volume":"382","author":"Leucht S.","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"e_1_2_14_32_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.37239","article-title":"Perioperative Factors Associated With Postoperative Delirium in Patients Undergoing Noncardiac Surgery: An Individual Patient Data Meta\u2010Analysis","volume":"6","author":"Sadeghirad B.","year":"2023","journal-title":"JAMA Network Open"},{"key":"e_1_2_14_33_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijnurstu.2024.104959","article-title":"Global Incidence and Prevalence of Delirium and Its Risk Factors in Medically Hospitalized Older Patients: A Systematic Review and Meta\u2010Analysis","volume":"162","author":"Wu C. R.","year":"2025","journal-title":"International Journal of Nursing Studies"},{"issue":"5","key":"e_1_2_14_34_1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2174\/1570159X14666161208153644","article-title":"Revisiting Antipsychotic\u2010Induced Akathisia: Current Issues and Prospective Challenges","volume":"15","author":"Salem H.","year":"2017","journal-title":"Current Neuropharmacology"},{"key":"e_1_2_14_35_1","article-title":"Haloperidol Induced Sudden Cardiac Arrest\u2010Report of a Very Rare Case and Review of Literature","volume":"2020","author":"Dar P. M.","year":"2020","journal-title":"Case Reports in Psychiatry"},{"key":"e_1_2_14_36_1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jpsychires.2025.05.065","article-title":"Comparative Cardiac Safety of Haloperidol vs. Chlorpromazine Among People Receiving Hemodialysis","volume":"188","author":"Nash R. P.","year":"2025","journal-title":"Journal of Psychiatric Research"},{"issue":"3","key":"e_1_2_14_37_1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.hrthm.2023.10.027","article-title":"Incidences, Risk Factors, and Clinical Correlates of Severe QT Prolongation After the Use of Quetiapine or Haloperidol","volume":"21","author":"Wang C. L.","year":"2024","journal-title":"Heart Rhythm"},{"issue":"3","key":"e_1_2_14_38_1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41401-025-01648-x","article-title":"ROS\u2010Induced Degradation of hERG Potassium Channels Contributes to Aripiprazole\u2010Induced Prolongation of the QTc Interval","volume":"47","author":"Cao Y. H.","year":"2026","journal-title":"Acta Pharmacologica Sinica"},{"issue":"1","key":"e_1_2_14_39_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejphar.2006.08.046","article-title":"Effect of Haloperidol on Transient Outward Potassium Current in Rat Ventricular Myocytes","volume":"550","author":"B\u00e9barov\u00e1 M.","year":"2006","journal-title":"European Journal of Pharmacology"},{"issue":"3","key":"e_1_2_14_40_1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cbi.2009.05.002","article-title":"Modulation of Haloperidol Induced Electrophysiological Alterations on Cardiac Action Potential by Various Risk Factors and Gender Difference","volume":"180","author":"Raghu K. G.","year":"2009","journal-title":"Chemico\u2010Biological Interactions"},{"issue":"6","key":"e_1_2_14_41_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0326804","article-title":"Major Adverse Cardiac Events With Haloperidol: A Meta\u2010Analysis","volume":"20","author":"Garcia M. C.","year":"2025","journal-title":"PLoS One"},{"issue":"8","key":"e_1_2_14_42_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.21037\/atm.2018.03.17","article-title":"Effects of Atypical Antipsychotic Drugs on QT Interval in Patients With Mental Disorders","volume":"6","author":"Aronow W. S.","year":"2018","journal-title":"Annals of Translational Medicine"},{"issue":"1","key":"e_1_2_14_43_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/schbul\/sbaa111","article-title":"Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia","volume":"47","author":"Taipale H.","year":"2021","journal-title":"Schizophrenia Bulletin"},{"issue":"16","key":"e_1_2_14_44_1","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1017\/S0033291724002873","article-title":"Suicidality and Use of Psychotropic Medications in Patients With Schizophrenia: A Prospective Cohort Study","volume":"54","author":"Str\u00f8mme M. F.","year":"2024","journal-title":"Psychological Medicine"},{"issue":"6","key":"e_1_2_14_45_1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/acps.13792","article-title":"Initiation and Discontinuation of Psychotropic Drugs Relative to Suicidal Behavior: A Danish Registry\u2010Based Study","volume":"151","author":"Reilev M.","year":"2025","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"31","key":"e_1_2_14_46_1","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2024.39.e226","article-title":"Psychotropic Medications Promote Time\u2010Dependent Reduction of Suicidal Ideation in Mood Disorder: A Prospective Cohort Study","volume":"39","author":"Yang J. H.","year":"2024","journal-title":"Journal of Korean Medical Science"},{"issue":"11","key":"e_1_2_14_47_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/14740338.2024.2399094","article-title":"Clozapine May Consistently Protect From Suicidal Behaviors While Other Antipsychotics May Lack a Specific Protective Effect: A Comprehensive VigiBase Study Interpreted in the Context of the Prior Literature","volume":"24","author":"De Las Cuevas C.","year":"2025","journal-title":"Expert Opinion on Drug Safety"},{"issue":"1","key":"e_1_2_14_48_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative Effects of 18 Antipsychotics on Metabolic Function in Patients With Schizophrenia, Predictors of Metabolic Dysregulation, and Association With Psychopathology: A Systematic Review and Network Meta\u2010Analysis","volume":"7","author":"Pillinger T.","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"e_1_2_14_49_1","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/obr.12934","article-title":"Effects of Antidepressant and Antipsychotic Use on Weight Gain: A Systematic Review","volume":"20","author":"Alonso\u2010Pedrero L.","year":"2019","journal-title":"Obesity Reviews"},{"issue":"3","key":"e_1_2_14_50_1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/schbul\/sbac001","article-title":"Antipsychotic\u2010Induced Weight Gain: Dose\u2010Response Meta\u2010Analysis of Randomized Controlled Trials","volume":"48","author":"Wu H.","year":"2022","journal-title":"Schizophrenia Bulletin"},{"key":"e_1_2_14_51_1","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.936589","article-title":"A Case of Exacerbation of Haloperidol\u2010Induced Rhabdomyolysis Following the Onset of COVID\u201019","volume":"23","author":"Takada K.","year":"2022","journal-title":"American Journal of Case Reports"},{"issue":"4","key":"e_1_2_14_52_1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0387-7604(00)00103-0","article-title":"Haloperidol\u2010Induced Rhabdomyolysis Without Neuroleptic Malignant Syndrome in a Handicapped Child","volume":"22","author":"Yoshikawa H.","year":"2000","journal-title":"Brain & Development"},{"issue":"5","key":"e_1_2_14_53_1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0897190013516509","article-title":"Antipsychotic Use and the Risk of Rhabdomyolysis","volume":"27","author":"Packard K.","year":"2014","journal-title":"Journal of Pharmacy Practice"},{"issue":"6","key":"e_1_2_14_54_1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/cap.2011.0134","article-title":"Rhabdomyolysis Reported for Children and Adolescents Treated With Antipsychotic Medicines: A Case Series Analysis","volume":"22","author":"Star K.","year":"2012","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"9","key":"e_1_2_14_55_1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.2174\/1389450121666200422084414","article-title":"The Association and Influencing Factors Between Antipsychotics Exposure and the Risk of VTE and PE: A Systematic Review and Meta\u2010Analysis","volume":"21","author":"Dai L.","year":"2020","journal-title":"Current Drug Targets"},{"key":"e_1_2_14_56_1","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1594334","article-title":"Sex Differences in Schizophrenia: Symptomatology, Treatment Efficacy and Adverse Effects","volume":"16","author":"Moniem I.","year":"2025","journal-title":"Frontiers in Psychiatry"},{"issue":"3","key":"e_1_2_14_57_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex Differences in Pharmacokinetics and Pharmacodynamics","volume":"48","author":"Soldin O. P.","year":"2009","journal-title":"Clinical Pharmacokinetics"},{"issue":"10","key":"e_1_2_14_58_1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1139\/cjpp-2018-0179","article-title":"Sex Differences in Cardiac Electrophysiology","volume":"96","author":"Ravens U.","year":"2018","journal-title":"Canadian Journal of Physiology and Pharmacology"},{"issue":"12","key":"e_1_2_14_59_1","first-page":"2649","article-title":"Crossing the Great Sex\u2010Specific Divide in Cardiac Electrophysiology","volume":"9","author":"Veeraraghavan R.","year":"2023","journal-title":"JACC: Clinical Electrophysiology"},{"issue":"10","key":"e_1_2_14_60_1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41575-025-01099-z","article-title":"Liver, Ageing and Disease","volume":"22","author":"Le Couteur D. G.","year":"2025","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"issue":"2","key":"e_1_2_14_61_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jamda.2019.10.022","article-title":"Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews","volume":"21","author":"Davies L. E.","year":"2020","journal-title":"Journal of the American Medical Directors Association"},{"issue":"9","key":"e_1_2_14_62_1","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/14740338.2024.2309223","article-title":"Utilizing Temporal Pattern of Adverse Event Reports to Identify Potential Late\u2010Onset Adverse Events","volume":"23","author":"Kim J. H.","year":"2024","journal-title":"Expert Opinion on Drug Safety"},{"issue":"5","key":"e_1_2_14_63_1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tips.2016.01.008","article-title":"Drug Tolerance: A Known Unknown in Translational Neuroscience","volume":"37","author":"Bespalov A.","year":"2016","journal-title":"Trends in Pharmacological Sciences"}],"container-title":["CNS Neuroscience &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cns.71217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cns.71217","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cns.71217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:57:53Z","timestamp":1792501073000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cns.71217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/cns.71217"],"URL":"https:\/\/doi.org\/10.1002\/cns.71217","archive":["Portico"],"relation":{},"ISSN":["1755-5930","1755-5949"],"issn-type":[{"value":"1755-5930","type":"print"},{"value":"1755-5949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-07-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71217"}}